The study identifies Barrett’s esophagus, colorectal lesions, inflammatory bowel disease, pancreatic cysts, biliopancreatic strictures and gastric diseases as conditions that could be benefit from the use of Cellvizio.
The technology form Mauna Kea hold both FDA 510(k) clearance and a European CE Mark.
More articles on gastroenterology:
Zacks reiterates Boston Scientific’s “neutral” rating
23 gastroenterologists making headlines
Smoking increases mortality risk in colorectal cancer patients
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
